10x Genomics Q2 revenue rises 3% excluding settlements; raises 2026 revenue forecast to $610-630M

10x Genomics reported Q2 2026 revenue of $151 million, up 3% from last year excluding patent settlement income. The company acquired Proteintech Genomics to enhance its multiomics capabilities and announced collaborations to advance cancer diagnostics. Despite a net loss of $17.9 million due to lower settlement gains, 10x Genomics raised its full-year revenue guidance to $610-$630 million, signaling confidence in growth prospects.